Nuwellis, Inc. — Form 8-K
Filed August 25, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Nuwellis presented an August 2026 investor presentation detailing H1 2026 revenue growth of 20% year-over-year and Q2 2026 gross margin expansion to 76% (vs. 56% prior year). The company is pursuing: Aquadex pediatric label expansion to ≥5 kg (FDA submission targeted year-end 2026); development of Vivian, a next-generation pediatric platform ($3M NIH grant); ClarityPRIME fluid monitoring system (2H 2027 launch); and a co-promotion agreement with Atrility Medical for AtriAmp cardiac rhythm monitoring. As of August 10, 2026, capitalization: 3,647,264 common shares, 5,859 preferred shares, 2,102,300 warrants, fully diluted 5,757,145 shares. Cash runway stated as through Q2 2027.
Why this rating
20% revenue growth and 20-point margin expansion are material for a $4.6M market-cap microcap; multiple product expansions and partnerships support trajectory. However, pre-revenue products (Vivian, ClarityPRIME) and cash runway concerns temper upside.
See more from August 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.